| James F Fries, MD | |
|
900 Blake Wilbur Dr, Palo Alto, CA 94304-2201 | |
| (650) 723-6961 | |
| Not Available |
| Full Name | James F Fries |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Rheumatology |
| Location | 900 Blake Wilbur Dr, Palo Alto, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922140367 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | C29908 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| James F Fries, MD 1000 Welch Rd, Suite 203, Palo Alto, CA 94304-1811 Ph: (650) 723-6003 | James F Fries, MD 900 Blake Wilbur Dr, Palo Alto, CA 94304-2201 Ph: (650) 723-6961 |
News Archive
New research has used a novel technology to successfully determine the sexual orientation of people from facial images or photographs. The accuracy of these techniques is reportedly more than those detected by humans. The study details are to be published n the Journal of Personality and Social Psychology. At present the study is available in a draft form.
The various health benefits from consuming dark chocolate are highly researched with claims that the antioxidants it contains can help people recover from a tough workout. But research from a University of Huddersfield student, studying Sports and Exercise Nutrition, has concluded it has no significant effect on a woman's muscle recovery post-exercise, posing a need for further research.
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced dosing of the first patient with CRMD-001 (a proprietary formulation of deferiprone) in a randomized, double-blind, placebo-controlled clinical trial.
Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) determined by a vote of 11-0 with 1 abstention that, in patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent (IMiD), the benefit-risk assessment is favorable for the use of Kyprolis.
Cancer patients on the National Health Service may soon be offered expensive life extending drugs which are currently denied to them. David Cameron has proposed on behalf of the Conservatives that the drugs that are licensed and prescribed by the health consultant of the patient should be made available to the cancer patient, irrespective of the NHS rationing.
› Verified 9 days ago
Daniel Joseph Razzano, M.D. Rheumatology Medicare: Medicare Enrolled Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000 | |
Mahnoosh Kuhbanani Seifoddini, M.D. Rheumatology Medicare: Medicare Enrolled Practice Location: 3801 Miranda Ave, Va Palo Alto Health Care System (111stc), Palo Alto, CA 94304 Phone: 209-946-3400 | |
Dr. Yusra Nazar Hussain, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 770 Welch Rd, Suite # 250, Palo Alto, CA 94304 Phone: 650-328-1676 Fax: 650-445-0911 | |
Dr. David Yao, M.D. Rheumatology Medicare: Medicare Enrolled Practice Location: 3801 Miranda Ave, Medical Services (111a), Palo Alto, CA 94304 Phone: 650-493-5000 | |
Dr. Franklin Perry, M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 2175 Park Blvd, Palo Alto, CA 94306 Phone: 650-330-3688 Fax: 650-330-3686 | |
Dr. Ryan Arthur Mcconnell, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 795 El Camino Real, Palo Alto, CA 94301 Phone: 650-853-2972 | |
Dr. Ann Margaretha Lowe, M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 420 Cambridge Ave, Unit 3, Palo Alto, CA 94306 Phone: 650-323-6614 |